Some of my recent work in pharmaceuticals focuses on firm strategies and how they impact consumer welfare, firm profits, and growth. I have worked on the valuation/welfare effects of introducing generics and second-generation (`me-too') drugs in a product market, the impact of additional presentations on the growth of a business unit, and now more recently on entry deterring effects of presentation proliferation and of product hopping. I have also worked on pay-for-delay deals in the European and American legal contexts and the cost of such (anticompetitive) deals. One of the main contributions of this work is the policy simulations that show which legislative changes are likely to make anti-competitive deals not possible and which might make the situation worse.
Concurrently, I am also working on policies to address the rise of antibacterial resistance
via
managing the demand for broad- vs narrow-spectrum antibiotics. I
also have current work on evaluating alcohol regulations such as a ban
on non-linear pricing or establishing price floors to curb excessive alcohol consumption and its heterogenous impact.
I have taught undergraduate, master’s, and Ph.D. students at various institutions. The bulk of my teaching has been to economics
majors to
whom I have taught microeconomics, econometrics, statistics, math
methods, industrial organization, and health economics at both the
graduate and undergraduate levels. But I also have
significant experience at teaching to non-economists. I have
taught Health Economics and Policy to medical and public
health students and Competition Economics and/IO to professionals from
regulatory agencies and consulting firms.
This page was last updated on May/07/2024